Abstract

Dr. Betul Celik* and Dr. Bulent Potur

ABSTRACT

Dear Editor, besides cancer chemotherapy and tumor arena, methotrexate (MTX), an anti-metabolite drug has been used for the treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and psoriasis since 1980s and has become the cornerstone of RA therapy.[1,2,3] Methotrexate acts on folate metabolism. It inhibits dihydrofolate reductase and prevents the synthesis of tetra hydro folate from dihydrofolate. As a result, the synthesis of timidilate, purine and ultimately DNA is blocked. Induction of apoptosis is, in part, responsible for its therapeutic effects,[4,5,6,7] so patient having this medication is closely monitored for possible side effects on liver but also for other organs.[8,9] To our knowledge, there is no information regarding interaction between heavy menorrhagia, endometrial hyperplasia, and MTX use in a woman at reproductive age. We here presented a patient who was admitted to our hospital because of a continued and heavy menorrhagia for 11 days.